HR 4117 115th Congress House

Competitive DRUGS Act of 2017

Official title: To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes.

Introduced: April 11, 2018 Introduced by: Doggett, Lloyd Democratic · Texas See on congress.gov

Health Administrative remediesBusiness expensesCivil actions and liabilityCompetition and antitrust

More subjectsShow fewer subjects

Federal Trade Commission (FTC)Income tax deductionsIntellectual propertyJudicial review and appealsMarketing and advertisingPrescription drugsResearch and development

Everywhere this bill has been 3 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Oct 27, 2017

Referred to the Subcommittee on Digital Commerce and Consumer Protection.

Oct 25, 2017

Referred to the Committee on Ways and Means, and in addition to the Committees on the Judiciary, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Oct 25, 2017

Introduced in House

Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

Latest action October 27, 2017

Referred to the Subcommittee on Digital Commerce and Consumer Protection.

Plain-English summary Congressional Research Service

Competitive Deals Resulting in Unleashed Generics and Savings Act of 2017 or the Competitive DRUGS Act of 2017

This bill establishes a series of requirements and prohibitions regarding certain patent infringement agreements between brand name and generic drug manufacturers in which the generic drug manufacturer agrees to delay the availability of applicable generic drugs. Among other things, the bill specifies that such agreements constitute an unfair method of competition and are subject to specified civil penalties.

Bill text 1 version

Introduced in House Formatted Text PDF Formatted XML

Source documents hosted by congress.gov.

Committees of jurisdiction 4

Commerce, Manufacturing, and Trade Subcommittee
House of Representatives · subcommittee of Energy and Commerce Committee
Energy and Commerce Committee
House of Representatives
Judiciary Committee
House of Representatives
Ways and Means Committee
House of Representatives

Cosponsors 27

Gallego, Ruben

Arizona · Nov 30, 2018

Waters, Maxine

California · Sep 4, 2018

Cleaver, Emanuel

Missouri · Jul 19, 2018

DeSaulnier, Mark

California · Jul 19, 2018

Wisconsin · Jul 19, 2018

Shea-Porter, Carol

· Jul 19, 2018

Thompson, Bennie G.

Mississippi · Jul 19, 2018

Larson, John B.

Connecticut · Jul 11, 2018

Norton, Eleanor Holmes

District of Columbia · Apr 11, 2018

Jayapal, Pramila

Washington · Nov 28, 2017

Welch, Peter

Vermont · Nov 28, 2017

Castor, Kathy

Florida · Oct 25, 2017

Chu, Judy

California · Oct 25, 2017

Cohen, Steve

Tennessee · Oct 25, 2017

DeLauro, Rosa L.

Connecticut · Oct 25, 2017

Kaptur, Marcy

Ohio · Oct 25, 2017

Khanna, Ro

California · Oct 25, 2017

Nadler, Jerrold

New York · Oct 25, 2017

Wisconsin · Oct 25, 2017

Raskin, Jamie

Maryland · Oct 25, 2017

Schakowsky, Janice D.

Illinois · Oct 25, 2017

Velázquez, Nydia M.

New York · Oct 25, 2017

Cite this page click to expand

APA

U.S. Congress. (2026). H.R. 4117: Competitive DRUGS Act of 2017. 115th Congress. Open America. https://openamerica.io/bill/115-HR-4117/

MLA

"H.R. 4117: Competitive DRUGS Act of 2017." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-HR-4117/.

Bluebook (legal)

H.R. 4117, 115th Cong. (2026), https://openamerica.io/bill/115-HR-4117/.

Markdown link

[H.R. 4117: Competitive DRUGS Act of 2017](https://openamerica.io/bill/115-HR-4117/)